USRE41390E1 - Trace elements - Google Patents

Trace elements Download PDF

Info

Publication number
USRE41390E1
USRE41390E1 US12/353,504 US35350409A USRE41390E US RE41390 E1 USRE41390 E1 US RE41390E1 US 35350409 A US35350409 A US 35350409A US RE41390 E USRE41390 E US RE41390E
Authority
US
United States
Prior art keywords
edta
solution
trace element
complex
element solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US12/353,504
Inventor
Robert Naylor Laurie
Lamertus Petrus Vosloo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warburton Technology Ltd
US Bank Trust Co NA
Original Assignee
Warburton Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warburton Technology Ltd filed Critical Warburton Technology Ltd
Priority to US12/353,504 priority Critical patent/USRE41390E1/en
Application granted granted Critical
Publication of USRE41390E1 publication Critical patent/USRE41390E1/en
Assigned to U.S. BANK NATIONAL ASSOCIATION reassignment U.S. BANK NATIONAL ASSOCIATION SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WARBURTON TECHNOLOGY LIMITED
Adjusted expiration legal-status Critical
Assigned to U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION reassignment U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION ASSIGNMENT AND ASSUMPTION AGREEMENT Assignors: U.S. BANK NATIONAL ASSOCIATION
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/40—Mineral licks, e.g. salt blocks
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Definitions

  • the invention discloses a method of preparing a trace element solution, which includes the steps of providing at least one EDTA-complex; of providing a sodium selenite solution; and of combining the EDTA-complex(es) and the sodium selenite solution.
  • the invention further discloses at least one EDTA complex prepared by using disodium EDTA or EDTA acid; selenium; and any other suitable mineral.
  • the present invention relates to trace elements.
  • U.S. Pat. No. 4,335,116 (Howard) discloses mineral-containing therapeutic compositions containing EDTA complexes of trace elements.
  • U.S. Pat. No. 4,335,116 utilises tetra-sodium EDTA, a selenium glycine complex, and metal chlorides for the preparation of the EDTA complexes.
  • the chloride ions cause contamination and each complex solution is to be made individually.
  • overnight time is required for complexing and heating up afterward to speed up the process requires extra apparatus.
  • mixtures are required, the individual solutions are to be blocked.
  • various concentrations as well as compositions are to be made, it can only be done in a cumbersome way, requiring extra apparatus.
  • a further problem may arise when mixtures of high concentration are needed. In certain cases it would be impossible to deliver them, because mixing is always accompanied by dilution.
  • EDTA refers to ethylene diaminotetraacetic acid (C 10 ,H 16 O 8 N 2 or (HO 2 CH 2 C) 2 NCH 2 CH 2 N-(CH 2 CO 2 H) 2 ).
  • a method of preparing a trace element solution includes the steps
  • these EDTA-complexes may be prepared in a single continuous process.
  • the EDTA-complex(es) may be prepared by using disodium EDTA or EDTA acid.
  • the EDTA-complex(es) may be prepared by using at least one selected from the group consisting of metal oxides, metal hydroxides and metal carbonates.
  • the EDTA-complex(es) may include at least one of the metal compounds selected from the group consisting of copper, manganese, zinc, molybdenum and chromium.
  • a trace element solution includes
  • the solution may be an injectable solution.
  • the solution may be a drenchable solution.
  • a stock lick includes
  • a method of providing trace elements to animals includes the steps of preparing a trace element solution set out herein and of providing the solution in a suitable quantity to an animal.
  • EDTA is suspended in a quantity of distilled water at 50° C. and is stirred continuously. In small proportions firstly sodium hydroxide (NaOH) and then zinc oxide (ZnO) are added in sequence. The pH of the clear solution obtained is measured and brought to 7, if necessary, by either the addition of NaOH (if acid) or EDTA (if alkaline). More distilled water is added to bring the zinc concentration to a predetermined level, and the solution is subsequently filtered.
  • NaOH sodium hydroxide
  • ZnO zinc oxide
  • the zinc concentration in the solution will be 20 mg/ml.
  • Manganese carbonate (MnCO 3 .xH 2 O) is used in place of zinc oxide.
  • the manganese concentration will be 20 mg/ml.
  • the copper concentration in the solution will be 10 mg/ml.
  • Chromium tri-chloride hexahydrate (CrCl 3 .6H 2 O) is used in the place of zinc oxide.
  • the chromium concentration in the solution will be 5 mg/ml.
  • the selenium concentration in the solution will be 5 mg/ml.
  • the method is a combination of the above methods under Examples 1, 2, 3, 4 and 5 and takes place as follows:
  • the zinc concentration will be 20 mg/ml, the manganese concentration 20 mg/ml, copper concentration 10 mg/ml, the chromium concentration 5 mg/ml and the selenium concentration 5 mg/ml.
  • Molybdenum tri-oxide (MoO 3 ) is suspended at room temperature in a quantity of water and stirred continuously. In portions in sequence firstly sodium hydroxide (NaOH) and then EDTA are added. The pH of the clear solution obtained is measured and it is brought to 7 if required, by adding either NaOH (if acid) or EDTA (if alkaline). More distilled water is added to bring the molybdenum concentration to a pre-determined value. The pH is changed to 6 by the addition of concentrated HCl. Filtration takes place.
  • NaOH sodium hydroxide
  • EDTA if alkaline
  • the molybdenum concentration will be 40 mg/ml.

Abstract

A method of preparing a trace element solution includes the steps of providing at least one EDTA-complex, providing a sodium selenite solution, and combining the EDTA-complex(es) and the sodium selenite solution to form a trace element solution. A EDTA complex is prepared by using disodium EDTA or EDTA acid, selenium, and any other suitable mineral.

Description

The invention discloses a method of preparing a trace element solution, which includes the steps of providing at least one EDTA-complex; of providing a sodium selenite solution; and of combining the EDTA-complex(es) and the sodium selenite solution. The invention further discloses at least one EDTA complex prepared by using disodium EDTA or EDTA acid; selenium; and any other suitable mineral.
FIELD OF INVENTION
The present invention relates to trace elements.
BACKGROUND TO INVENTION
It has been found that there is a deficiency of certain trace elements in pastures for livestock in particular areas in South Africa and also in other countries. Various suggestions have been made to provide the required trace elements to such animals. Different chemical compounds and complexes have been investigated for applying the trace elements by way of licks, drenches or injections.
In general the problem with injectable solutions is that there are too low concentrations of the minerals in the solutions. This means that relatively large quantities have to be injected, which in turn cause tissue damage and also abscesses at the site of injection. Furthermore, it is generally the case that different trace elements seldomly are individually sufficient. This means that two or more trace element solutions have to be provided by way of separate injections.
U.S. Pat. No. 4,335,116 (Howard) discloses mineral-containing therapeutic compositions containing EDTA complexes of trace elements. Notably, U.S. Pat. No. 4,335,116 utilises tetra-sodium EDTA, a selenium glycine complex, and metal chlorides for the preparation of the EDTA complexes. Unfortunately, the chloride ions cause contamination and each complex solution is to be made individually. Furthermore, overnight time is required for complexing and heating up afterward to speed up the process requires extra apparatus. If mixtures are required, the individual solutions are to be blocked. If various concentrations as well as compositions are to be made, it can only be done in a cumbersome way, requiring extra apparatus. A further problem may arise when mixtures of high concentration are needed. In certain cases it would be impossible to deliver them, because mixing is always accompanied by dilution.
It is an object of the invention to suggest methods and means for overcoming these problems.
In the specification and claims the expression EDTA refers to ethylene diaminotetraacetic acid (C10,H16O8N2 or (HO2CH2C)2NCH2CH2N-(CH2CO2H)2).
SUMMARY OF INVENTION
According to the invention, a method of preparing a trace element solution includes the steps
    • (a) of providing at least one EDTA-complex;
    • (b) of providing a sodium selenite solution; and
    • (c) of combining the EDTA-complex(es) and the sodium selenite solution.
If more than one EDTA-complex is used, these EDTA-complexes may be prepared in a single continuous process.
The EDTA-complex(es) may be prepared by using disodium EDTA or EDTA acid.
The EDTA-complex(es) may be prepared by using at least one selected from the group consisting of metal oxides, metal hydroxides and metal carbonates.
The EDTA-complex(es) may include at least one of the metal compounds selected from the group consisting of copper, manganese, zinc, molybdenum and chromium.
A trace element solution as prepared by a method as set out herein.
Also, according to the invention, a trace element solution includes
    • (a) at least one EDTA complex prepared by using disodium EDTA or EDTA acid;
    • (b) selenium; and
    • (c) any other suitable mineral.
The solution may be an injectable solution.
The solution may be a drenchable solution.
Further according to the invention a stock lick includes
    • (a) at least one EDTA complex prepared by using disodium EDTA or EDTA acid;
    • (b) selenium; and
    • (c) any other suitable mineral.
Also, according to the invention, a method of providing trace elements to animals, such as livestock includes the steps of preparing a trace element solution set out herein and of providing the solution in a suitable quantity to an animal.
DESCRIPTION OF EXAMPLES
The invention will now be described by way of example of injectable solutions in accordance with the invention.
Example 1 Di-Sodium Zinc Ethylene Diamino Tetra Acetate (C10H12O8N2ZnNa2) in Water Solution
EDTA is suspended in a quantity of distilled water at 50° C. and is stirred continuously. In small proportions firstly sodium hydroxide (NaOH) and then zinc oxide (ZnO) are added in sequence. The pH of the clear solution obtained is measured and brought to 7, if necessary, by either the addition of NaOH (if acid) or EDTA (if alkaline). More distilled water is added to bring the zinc concentration to a predetermined level, and the solution is subsequently filtered.
If 25.16 g zinc oxide, 90.37 g EDTA and 24.74 g NaOH are used and the total volume is 1 liter, the zinc concentration in the solution will be 20 mg/ml.
Example 2 Di-Sodium Manganese Ethylene Diamino Tetra Acetate (C10H12O8N2MnNa2) in Water Solution
The same method as under example 1 is used with the following variation:
Manganese carbonate (MnCO3.xH2O) is used in place of zinc oxide.
If 45.45 g manganese carbonate, 106.39 g EDTA and 29.12 g NaOH are used, and the total volume is 1 liter, the manganese concentration will be 20 mg/ml.
Example 3 Di-Sodium Copper Ethylene Diamino Tetra Acetate (C10H12O8N2CuNa2) in Water Solution
The same method as under Example 1 is followed but with the following variation:
Basic copper carbonate (CuCO3Cu(OH)2.H2O) is used in place of the zinc oxide.
If 18.81 g basic copper carbonate, 45.99 g EDTA and 12.59 g NaOH are used, and the total volume is 1 liter, then the copper concentration in the solution will be 10 mg/ml.
Example 4 Mono-Sodium Chromium Diamino Tetra Acetate (C10H12O8N2CrNa) in Water Solution
The same method as under Example 1 is followed, but with the following variation:
Chromium tri-chloride hexahydrate (CrCl3.6H2O) is used in the place of zinc oxide.
If 25.62 g chromium tri-chloride hexahydrate, 31.59 g EDTA and 15.38 g sodium hydroxide are used and the total is 1 liter, the chromium concentration in the solution will be 5 mg/ml.
Example 5 Sodium Selenite (Na2SeO3.H2O) Solution in Water
If 12.09 g sodium selenite is used and the total volume is 1 liter, the selenium concentration in the solution will be 5 mg/ml.
Example 6 A Mixture of the Compounds of Examples 1 to 5
The method is a combination of the above methods under Examples 1, 2, 3, 4 and 5 and takes place as follows:
    • 1. The zinc preparation as per Example 1 is prepared.
    • 2. To this added (in the same container) the chemicals as used for Example 2 for the preparation of the manganese compound.
    • 3. Then the chemicals used as under Example 3 for the preparation of the copper compound are added.
    • 4. At this stage the pH is brought to 7 as described under Example 1 above.
    • 5. Subsequently the chemicals used as under Example 4 for the preparation of the chromium compound are added.
    • 6. Lastly the chemicals used as under Example 5 are added.
    • 7. Finally the total volume is adapted by the addition of distilled water.
    • 8. Filtration takes place.
If 25.16 g zinc oxide, 45.45 g manganese carbonate, 18.81 g basic copper carbonate, 25.62 g chromium tri-chloride hexahydrate, 12.09 g sodium selenite, 274.34 g EDTA and 81.83 g NaOH are used, and if the total volume is 1 liter, then the zinc concentration will be 20 mg/ml, the manganese concentration 20 mg/ml, copper concentration 10 mg/ml, the chromium concentration 5 mg/ml and the selenium concentration 5 mg/ml.
Example 7 Tetra Sodium Molybdenum Tri-Oxide Ethylene Diamino Tetra Acetate (C10H12O8N2MoO3Na4) in Water Solution
Molybdenum tri-oxide (MoO3) is suspended at room temperature in a quantity of water and stirred continuously. In portions in sequence firstly sodium hydroxide (NaOH) and then EDTA are added. The pH of the clear solution obtained is measured and it is brought to 7 if required, by adding either NaOH (if acid) or EDTA (if alkaline). More distilled water is added to bring the molybdenum concentration to a pre-determined value. The pH is changed to 6 by the addition of concentrated HCl. Filtration takes place.
If 60.02 g MoO3, 66.71 g NaOH and 121.84 g EDTA are used and if the volume is 1 liter, then the molybdenum concentration will be 40 mg/ml.
In all of the above examples the order of mixing the chemicals may be changed to some extent without any influence on the products formed.
All of the above products can be obtained as solids by evaporation of the appropriate solutions.
All of the above-mentioned chemicals may be substituted by others, provided the substitute are used in equivalent quantities. The particulars are as follows:
    • 1. The di-sodium salt of EDTA in place of EDTA acid.
    • 2. Basic zinc carbonate (2ZnCO3.3Zn(OH)2) or zinc hydroxide (Zn(OH)2) in place of zinc oxide.
    • 3. Manganese hydroxide (Mn(OH)2) in place of manganese carbonate.
    • 4. Cupric hydroxide (Cu(OH)2) or cupric oxide (CuO) in place of basic copper carbonate.
    • 5. Anhydrous chromium tri-chloride (CrCl3) in place of chromium tri-chloride hexahydrate.
    • 6. Sodium molybdate (Na2MoO4) in place of molybdenum tri-oxide.

Claims (7)

1. A method of preparing a trace element solution, said method consisting essentially of the steps of:
(a) preparing a single solution comprising more than one EDTA-complex as a sodium salt in a single continuous process by suspending either disodium EDTA in water or suspending EDTA acid in water with sodium hydroxide, and adding a adding at least one metal compound selected from the group consisting of metal oxides, metal hydroxides and metal carbonates to the EDTA solution to form the EDTA-complex, wherein the at least one metal compound comprises at least chromium; and
(b) adding sodium selenite to the solution of EDTA-complexes to form the trace element solution in which the molar ratio of selenium in the form of sodium selenite to the metal compounds to the EDTA complexes varies between 1:4.8:4.8 and 1:19:19.
2. A method as claimed in claim 1, in which the EDTA-complexes comprise at least one of the metal cation components selected from the group consisting of copper, manganese, zinc, zinc and molybdenum and chromium .
3. A trace element solution as prepared by a method as claimed in claim 1.
4. A trace element solution as claimed in claim 3, which is an injectable solution.
5. A trace element solution as claimed in claim 3, which is a drenchable solution.
6. A stock lick, which comprises a trace element solution as prepared by a method as claimed in claim 1.
7. A method of providing trace elements to animals, such as livestock, which comprises the steps of preparing a trace element solution as claimed in claim 1, and of providing the solution in a suitable quantity to an animal.
US12/353,504 2000-08-28 2009-01-14 Trace elements Expired - Lifetime USRE41390E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/353,504 USRE41390E1 (en) 2000-08-28 2009-01-14 Trace elements

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ZA200004456 2000-08-28
ZA2000/4456 2000-08-28
US09/935,550 US6638539B2 (en) 2000-08-28 2001-08-24 Trace elements
US12/353,504 USRE41390E1 (en) 2000-08-28 2009-01-14 Trace elements

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/935,550 Reissue US6638539B2 (en) 2000-08-28 2001-08-24 Trace elements

Publications (1)

Publication Number Publication Date
USRE41390E1 true USRE41390E1 (en) 2010-06-22

Family

ID=25588884

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/935,550 Ceased US6638539B2 (en) 2000-08-28 2001-08-24 Trace elements
US10/693,955 Expired - Lifetime US8231910B2 (en) 2000-08-28 2003-10-28 Trace elements
US12/353,504 Expired - Lifetime USRE41390E1 (en) 2000-08-28 2009-01-14 Trace elements

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/935,550 Ceased US6638539B2 (en) 2000-08-28 2001-08-24 Trace elements
US10/693,955 Expired - Lifetime US8231910B2 (en) 2000-08-28 2003-10-28 Trace elements

Country Status (11)

Country Link
US (3) US6638539B2 (en)
EP (1) EP1339416B1 (en)
AU (2) AU7999401A (en)
BR (1) BR0113668A8 (en)
CA (2) CA2420766C (en)
DK (1) DK1339416T3 (en)
ES (1) ES2394080T3 (en)
MX (1) MXPA03001836A (en)
NZ (1) NZ524848A (en)
WO (1) WO2002017933A1 (en)
ZA (1) ZA200106875B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2420766C (en) * 2000-08-28 2007-12-11 Warburton Technology Limited Trace elements
AU2002351537A1 (en) * 2002-10-31 2004-06-18 Piotr Zajac Feed additive and process for manufacturing thereof
US7285292B2 (en) * 2004-04-29 2007-10-23 Warburton Technology Limited Trace elements
PL4026431T3 (en) * 2004-05-03 2023-06-12 Warburton Technology Limited Injectable trace element solution for livestock
AU2005281393B2 (en) * 2004-09-09 2012-01-12 Virbac (Australia) Pty Ltd Trace elements
HRP20211859T1 (en) 2008-12-09 2022-03-04 Warburton Technology Limited Trace elements
US20110076341A1 (en) * 2009-09-25 2011-03-31 William Alfred Smith Trace elements
PL2849764T3 (en) 2012-05-14 2020-03-31 Warburton Technology Limited Trace element solution
CN116270734A (en) 2015-10-09 2023-06-23 沃伯顿科技有限公司 Trace element solution
GB201607814D0 (en) 2016-05-04 2016-06-15 5D Health Prot Group Ltd Anti-microbial compositions
US20220257635A1 (en) * 2019-07-12 2022-08-18 Chemvet Australia Pty Ltd Injectable nutritional supplement

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335116A (en) * 1980-10-07 1982-06-15 University Patents, Inc. Mineral-containing therapeutic compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU187467B (en) 1981-11-02 1986-01-28 Vetoemagtermeltetoe Es Ertekesitoe Vallalat,Hu Method for producing preparation suitable for preventing health deterioration of alimentary origin promoting the utilization of fodder of animals
HUT58194A (en) * 1990-08-29 1992-02-28 Nyirseg Konzervipari Vallalat Method for producing foodstuff-preparations suitable for introducing biologically important micro- and macro-elements
DE19617185A1 (en) * 1996-04-29 1997-10-30 Muehle Ebert Dielheim Gmbh New horse feedstuffs containing bioactive trace metals
CA2420766C (en) * 2000-08-28 2007-12-11 Warburton Technology Limited Trace elements
US20030021836A1 (en) * 2001-04-20 2003-01-30 Spencer Feldman Magnesium di-potassium EDTA complex and method of administration
US7670688B2 (en) * 2001-06-25 2010-03-02 Applied Materials, Inc. Erosion-resistant components for plasma process chambers
US7285292B2 (en) * 2004-04-29 2007-10-23 Warburton Technology Limited Trace elements

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335116A (en) * 1980-10-07 1982-06-15 University Patents, Inc. Mineral-containing therapeutic compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Package label from product sold from 1999-2001, identified as Multimin(TM).
Package label from product sold from 1999-2001, identified as Multimin™.

Also Published As

Publication number Publication date
EP1339416B1 (en) 2012-11-07
US8231910B2 (en) 2012-07-31
CA2420766A1 (en) 2002-03-07
MXPA03001836A (en) 2004-03-26
EP1339416A4 (en) 2004-02-04
US20020068079A1 (en) 2002-06-06
NZ524848A (en) 2004-07-30
CA2420766C (en) 2007-12-11
EP1339416A1 (en) 2003-09-03
ES2394080T3 (en) 2013-01-17
US20040235945A1 (en) 2004-11-25
CA2589059A1 (en) 2002-03-07
WO2002017933A1 (en) 2002-03-07
US6638539B2 (en) 2003-10-28
AU2001279994B2 (en) 2004-09-02
CA2589059C (en) 2011-10-04
ZA200106875B (en) 2001-09-05
BR0113668A (en) 2003-06-03
DK1339416T3 (en) 2013-02-18
BR0113668A8 (en) 2018-03-06
BRPI0113668B1 (en) 2015-08-11
AU7999401A (en) 2002-03-13

Similar Documents

Publication Publication Date Title
USRE41390E1 (en) Trace elements
US10729772B2 (en) Trace elements
US11000544B2 (en) Trace elements
CA2556813C (en) Trace elements
AU2001279994A1 (en) Trace elements
US20110076341A1 (en) Trace elements
US11564940B2 (en) Trace element solution

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: U.S. BANK NATIONAL ASSOCIATION, NORTH CAROLINA

Free format text: SECURITY INTEREST;ASSIGNOR:WARBURTON TECHNOLOGY LIMITED;REEL/FRAME:051363/0001

Effective date: 20191206

AS Assignment

Owner name: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, NORTH CAROLINA

Free format text: ASSIGNMENT AND ASSUMPTION AGREEMENT;ASSIGNOR:U.S. BANK NATIONAL ASSOCIATION;REEL/FRAME:063115/0486

Effective date: 20220128